Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway

Neuroscience

Volumn 257, Issue , 2014, Pages 1-10

  Chen, C ^a   Li, X H ^a   Tu, Y ^a   Sun, H T ^a   Liang, H Q ^a   Cheng, S X ^a   Zhang, S ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Alzheimer's disease; Glycation; Glycogen synthase kinase 3; Receptor of advanced glycation endproducts; amyloid

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITHIUM CHLORIDE; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DISEASE EXACERBATION; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AD; ADVANCED GLYCATION END-PRODUCTS; AGES; ALZHEIMER'S DISEASE; AMYLOID PRECURSOR PROTEIN; ANTERIOR TO POSTERIOR; AP; APP; AΒ; AΒ-AGE; DORSAL TO VENTRAL; DV; EDTA; EPSP; ETHYLENEDIAMINETETRAACETIC ACID; EXCITATORY POSTSYNAPTIC POTENTIAL; GLYCATED AΒ; GLYCATION; GLYCOGEN SYNTHASE KINASE 3; GSK3; HFS; HIGH-FREQUENCY STIMULATION; LONG-TERM POTENTIATION; LTP; MAPK; MID TO LATERAL; MITOGEN-ACTIVATED PROTEIN KINASES; ML; NF-ΚB; NUCLEAR FACTOR ΚB; PAB; PB; PCR; PHOSPHATE BUFFER; POLYCLONAL ANTIBODY; POLYMERASE CHAIN REACTION; POPULATION SPIKE; POSTSYNAPTIC DENSITY; PS; PSD; RAGE; RECEPTOR FOR AGES; RECEPTOR OF ADVANCED GLYCATION ENDPRODUCTS; SYNTHASE KINASE-3; Β-AMYLOID;

AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; GLYCOSYLATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMBRANE PROTEINS; NEURONS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, IMMUNOLOGIC; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84888231522     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.056     Document Type: Article

References (54)

1. Arancio O., Zhang H.P., Chen X., Lin C., Trinchese F., Puzzo D., Liu S., Hegde A., Yan S.F., Stern A., Luddy J.S., Lue L.F., Walker D.G., Roher A., Buttini M., Mucke L., Li W., Schmidt A.M., Kindy M., Hyslop P.A., Stern D.M., Du Yan S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004, 23:4096-4105. [PubMed: 15457210].
2. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002, 36:1307-1313. [PubMed: 12607822].
3. Chen X., Walker D.G., Schmidt A.M., Arancio O., Lue L.F., Yan S.D. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007, 7:735-742. [PubMed: 18331231].
4. Choei H., Sasaki N., Takeuchi M., Yoshida T., Ukai W., Yamagishi S., Kikuchi S., Saito T. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 2004, 108:189-193. [PubMed: 15221334].
5. Du Yan S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., Rajavashisth T., Chen X., Godman G.C., Stern D., Schmidt A.M. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997, 94:5296-5301. [PubMed: 9144231].
6. Fawver J.N., Schall H.E., Petrofes Chapa R.D., Zhu X., Murray I.V. Amyloid-beta metabolite sensing: biochemical linking of glycation modification and misfolding. J Alzheimer Dis 2012, 30:63-73. [PubMed: 22406446].
7. Gasic-Milenkovic J., Dukic-Stefanovic S., Deuther-Conrad W., Gärtner U., Münch G. Beta-amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -gamma and 'advanced glycation endproducts' in a murine microglia cell line. Eur J Neurosci 2003, 17:813-821. [PubMed: 12603271].
8. Glaser E.M., Van der Loos H. Analysis of thick brain sections by obverse-reverse computer microscopy: application of a new, high clarity Golgi-Nissl stain. J Neurosci Methods 1981, 4:117-125. [PubMed: 6168870].
9. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135. [PubMed: 6236805].
10. Guglielmotto M., Aragno M., Tamagno E., Vercellinatto I., Visentin S., Medana C., Catalano M.G., Smith M.A., Perry G., Danni O., Boccuzzi G., Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2012, 33(196):e113-e127. [PubMed: 20638753].
11. Guimaraes E.L., Empsen C., Geerts A., van Grunsven L.A. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 2010, 52:389-397. [PubMed: 20133001].
12. Guix F.X., Ill-Raga G., Bravo R., Nakaya T., de Fabritiis G., Coma M., Miscione G.P., Villa-Freixa J., Suzuki T., Fernandez-Busquets X., Valverde M.A., de Strooper B., Munoz F.J. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Brain 2009, 132:1335-1345. [PubMed: 19251756].
13. Hadding A., Kaltschmidt B., Kaltschmidt C. Overexpression of receptor of advanced glycation end products hypersensitizes cells for amyloid beta peptide-induced cell death. Biochim Biophys Acta 2004, 1691:67-72. [PubMed: 15053925].
14. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102. [PubMed: 8810256].
15. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481. [PubMed: 14747300].
16. Kosik K.S. Alzheimer's disease: a cell biological perspective. Science 1992, 256:780-783. [PubMed: 1589757].
17. Krautwald M., Munch G. Advanced glycation end products as biomarkers and gerontotoxins - a basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Exp Gerontol 2010, 45:744-751. [PubMed: 20211718].
18. Kuhla B., Loske C., GarciaDeArriba S., Schinzel R., Huber J., Münch G. Differential effects of "advanced glycation endproducts" and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 2004, 111:427-439. [Pubmed: 14991463].
19. LaFerla F.M., Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005, 11:170-176.
20. Li X.H., Chen C., Tu Y., Sun H.T., Zhao M.L., Cheng S.X., Qu Y., Zhang S. Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3. Mol Neurobiol 2013, 48:490-499. [PubMed: 23475611].
21. Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L., Liu R., Wang J.Z., Zhou X.W. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis 2013, 4:e673. [PubMed: 23764854].
22. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012, 33:1400-1410. [PubMed: 21450369].
23. Li X.H., Xie J.Z., Jiang X., Lv B.L., Cheng X.S., Du L.L., Zhang J.Y., Wang J.Z., Zhou X.W. Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromol Med 2012, 14:338-348. [PubMed: 22798221].
24. Loske C., Gerdemann A., Schepl W., Wycislo M., Schinzel R., Palm D., Riederer P., Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 2000, 267:4171-4178. [PubMed: 10866821].
25. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001, 22:187-194. [PubMed: 11182468].
26. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Bio Med 1997, 23:134-147. [PubMed: 9165306].
27. Meneghini V., Bortolotto V., Francese M.T., Dellarole A., Carraro L., Terzieva S., Grilli M. High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-kappaB axis: relevance for Alzheimer's disease. J Neurosci 2013, 33:6047-6059. [PubMed: 23554486].
28. Miller M.C., Tavares R., Johanson C.E., Hovanesian V., Donahue J.E., Gonzalez L., Silverberg G.D., Stopa E.G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008, 1230:273-280. [PubMed: 18657529].
29. Mruthinti S., Hill W.D., Swamy-Mruthinti S., Buccafusco J.J. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites. J Mol Neurosci 2003, 20:223-232. [PubMed: 14501001].
30. Mruthinti S., Sood A., Humphrey C.L., Swamy-Mruthinti S., Buccafusco J.J. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products. Neuroscience 2006, 142:463-473. [PubMed: 16890367].
31. Münch G., Apelt J., Rosemarie-Kientsch-Engel, Stahl P., Lüth H.J., Schliebs R. Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. J Neurochem 2003, 86:283-289. [PubMed: 12871569].
32. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992, 267:14998-15004. [PubMed: 1378843].
33. Origlia N., Righi M., Capsoni S., Cattaneo A., Fang F., Stern D.M., Chen J.X., Schmidt A.M., Arancio O., Yan S.D., Domenici L. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 2008, 28:3521-3530. [PubMed: 18367618].
34. Paxinos G., Watson C.J. The rat brain in stereotaxic coordinates 1996, Academic Press, New York. second ed.
35. Perry G., Castellani R.J., Hirai K., Smith M.A. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimer Dis 1998, 1:45-55. [PubMed:12214011].
36. Ramirez M., Hernandez-Montoya J., Sanchez-Serrano S.L., Ordaz B., Ferraro S., Quintero H., Pena-Ortega F., Lamas M. GABA-mediated induction of early neuronal markers expression in postnatal rat progenitor cells in culture. Neuroscience 2012, 224:210-222. [PubMed: 22940108].
37. Sasaki N., Toki S., Chowei H., Saito T., Nakano N., Hayashi Y., Takeuchi M., Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001, 888:256-262. [PubMed: 11150482].
38. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992, 267:14987-14997. [PubMed: 1321822].
39. Smith M.A., Sayre L.M., Vitek M.P., Monnier V.M., Perry G. Early AGEing and Alzheimer's. Nature 1995, 374:316. [PubMed: 7885469].
40. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994, 91:5710-5714. [PubMed: 8202552].
41. Soares E., Prediger R.D., Nunes S., Castro A.A., Viana S.D., Lemos C., De Souza C.M., Agostinho P.M., Cunha R.A., Carvalho E., Fontes Ribeiro C.A., Reis F., Pereira F.C. Spatial memory impairments in a prediabetic rat model. Neuroscience 2013, 250:565-577. [PubMed: 23912035].
42. Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011, 32:763-777. [PubMed: 19464758].
43. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J Alzheimers Dis 2005, 7:63-80. [PubMed: 15750215].
44. Sturchler E., Galichet A., Weibel M., Leclerc E., Heizmann C.W. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 2008, 28:5149-5158. [PubMed: 18480271].
45. Takuma K., Fang F., Zhang W., Yan S., Fukuzaki E., Du H., Sosunov A., McKhann G., Funatsu Y., Nakamichi N., Nagai T., Mizoguchi H., Ibi D., Hori O., Ogawa S., Stern D.M., Yamada K., Yan S.S. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA 2009, 106:20021-20026. [PubMed: 19901339].
46. Valente T., Gella A., Fernandez-Busquets X., Unzeta M., Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010, 37:67-76. [PubMed: 19778613].
47. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:4766-4770. [PubMed: 8197133].
48. Wilson J.S., Mruthinti S., Buccafusco J.J., Schade R.F., Mitchell M.B., Harrell D.U., Gulati N.K., Miller L.S. Anti-RAGE and Abeta immunoglobulin levels are related to dementia level and cognitive performance. J Gerontol A Biol Sci Med Sci 2009, 64:264-271. [PubMed: 19196906].
49. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691. [PubMed: 8751438].
50. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., Smith M.A. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994, 91:7787-7791. [PubMed: 8052661].
51. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., Nawroth P. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995, 1:693-699. [PubMed: 7585153].
52. Yang Y., Song W. Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience 2013, 250C:140-150. [PubMed: 23867771].
53. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16:921-932. [PubMed: 8630250].
54. Zhu L.Q., Wang S.H., Liu D., Yin Y.Y., Tian Q., Wang X.C., Wang Q., Chen J.G., Wang J.Z. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 2007, 27:12211-12220. [PubMed: 17989287].